Professor Michael Barry:

I do not agree with the Bill because, essentially, its implications are enormous for the drugs budget. Already this year, if we go to September for the orphan drugs and if we imagine that Bill were here, whereby there is no assessment, it would cost €140 million. It will probably cost €200 million a year. That is what it will cost. If people want to vote for that and want to pay that much money, so be it - I will not take it personally - but, from a financial aspect for the HSE, I would say no. I am very clear on that.